ArticleProceedings of the National Academy of Sciences of the United States of America2005
Differential induction of IgE-mediated anaphylaxis after soluble vs. cell-bound tolerogenic peptide therapy of autoimmune encephalomyelitis.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 93 citations in OpenAlex.
- Modeling pathogenic B cell function in experimental autoimmune encephalomyelitis.Journal of immunology (Baltimore, Md. : 1950) · 2026Review
- Overcoming Synthetic Challenges and Evaluating in Vivo Efficacy of the MOG-Fc-Bifunctional Peptide Inhibitor for EAE in Mice.Bioconjugate chemistry · 2025Article
- Remote loading of an autoantigen in PLGA nanoparticles for the treatment of multiple sclerosis.Journal of controlled release : official journal of the Controlled Release Society · 2025Article
- Soluble antigen arrays provide increased efficacy and safety over free peptides for tolerogenic immunotherapy.Frontiers in immunology · 2024Article
- Antigen-specific immunotherapy with apitopes suppresses generation of FVIII inhibitor antibodies in HLA-transgenic mice.Blood advances · 2022Article
- Mechanistic contributions of Kupffer cells and liver sinusoidal endothelial cells in nanoparticle-induced antigen-specific immune tolerance.Biomaterials · 2022Article
- Immune Checkpoint Ligand Bioengineered Schwann Cells as Antigen-Specific Therapy for Experimental Autoimmune Encephalomyelitis.Advanced materials (Deerfield Beach, Fla.) · 2022Article
- Antigen-Specific Immune Tolerance in Multiple Sclerosis-Promising Approaches and How to Bring Them to Patients.Frontiers in immunology · 2021Review
- Prevention of EAE by tolerogenic vaccination with PEGylated antigenic peptides.Therapeutic advances in chronic disease · 2021Article
- Oligodendrocyte-derived extracellular vesicles as antigen-specific therapy for autoimmune neuroinflammation in mice.Science translational medicine · 2020Article
- Molecular Interventions towards Multiple Sclerosis Treatment.Brain sciences · 2020Review
- Tolerogenic Immunomodulation by PEGylated Antigenic Peptides.Frontiers in immunology · 2020Article
- Long-term tolerance of islet allografts in nonhuman primates induced by apoptotic donor leukocytes.Nature communications · 2019Article
- Bioconjugate Strategies for the Induction of Antigen-Specific Tolerance in Autoimmune Diseases.Bioconjugate chemistry · 2018Review
- Multipeptide-coupled nanoparticles induce tolerance in 'humanised' HLA-transgenic mice and inhibit diabetogenic CD8Diabetologia · 2017Article
- Modulating the immune system through nanotechnology.Seminars in immunology · 2017Review
- Controlled Delivery of Single or Multiple Antigens in Tolerogenic Nanoparticles Using Peptide-Polymer Bioconjugates.Molecular therapy : the journal of the American Society of Gene Therapy · 2017Article
- Immune Tolerance for Autoimmune Disease and Cell Transplantation.Annual review of biomedical engineering · 2016Review
- Nano- and micro-based systems for immunotolerance induction in multiple sclerosis.Human vaccines & immunotherapeutics · 2016Article
- Biodegradable antigen-associated PLG nanoparticles tolerize Th2-mediated allergic airway inflammation pre- and postsensitization.Proceedings of the National Academy of Sciences of the United States of America · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
The ability of different forms of myelin peptides to induce tolerance for the treatment of preestablished murine experimental autoimmune encephalomyelitis (EAE), a mouse model of multiple sclerosis, was evaluated. i.v. administration of myelin peptide-pulsed, ethylene carbodiimide-fixed syngeneic splenocytes, but not soluble myelin peptide monomers or oligomers, proved exceedingly effective at treating preestablished EAE, resulting in amelioration of disease progression. In addition to the lack of therapeutic efficacy of soluble peptide and peptide oligomer, administering them i.v. after the onset of clinical symptoms in many but not all peptide-induced EAE models led to a rapid-onset anaphylactic reaction characterized by respiratory distress, erythema, decreased body temperature, unresponsiveness, and, often, death. By using anti-IgE antibody treatments and mice with targeted mutations of the FcgammaRIII alpha-chain or the common gamma-chain of FcepsilonRI and FcgammaRI/III, we demonstrate that IgE crosslinking of FcepsilonRI appears to be necessary and sufficient for myelin peptide-induced anaphylaxis. The implications of these findings to myelin peptide/protein tolerance strategies for the treatment of multiple sclerosis are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.